Geode Capital Management LLC Has $87.56 Million Position in COPT Defense Properties $CDP

Geode Capital Management LLC grew its stake in COPT Defense Properties (NYSE:CDP) by 0.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,149,130 shares of the company’s stock after purchasing an additional 17,049 shares during the period. Geode Capital Management LLC owned about 2.78% of COPT Defense Properties worth $87,558,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of COPT Defense Properties by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 17,127,858 shares of the company’s stock valued at $476,154,000 after purchasing an additional 128,583 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of COPT Defense Properties by 16.8% in the 3rd quarter. Alliancebernstein L.P. now owns 8,457,373 shares of the company’s stock valued at $245,771,000 after purchasing an additional 1,215,936 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of COPT Defense Properties by 7.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,566,073 shares of the company’s stock valued at $103,630,000 after purchasing an additional 253,558 shares in the last quarter. Channing Capital Management LLC boosted its stake in shares of COPT Defense Properties by 21.0% in the 3rd quarter. Channing Capital Management LLC now owns 2,913,596 shares of the company’s stock valued at $84,669,000 after purchasing an additional 506,593 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of COPT Defense Properties by 5.4% in the 2nd quarter. Bank of America Corp DE now owns 2,577,065 shares of the company’s stock valued at $71,075,000 after purchasing an additional 131,287 shares in the last quarter.

Wall Street Analysts Forecast Growth

CDP has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their price target on shares of COPT Defense Properties from $33.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, May 15th. Weiss Ratings raised shares of COPT Defense Properties from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, April 21st. Wells Fargo & Company upped their price target on shares of COPT Defense Properties from $35.00 to $36.00 and gave the company an “overweight” rating in a research report on Monday, June 1st. Evercore restated an “outperform” rating and issued a $38.00 price target on shares of COPT Defense Properties in a research report on Tuesday, April 28th. Finally, Citigroup upped their price target on shares of COPT Defense Properties from $29.00 to $34.00 and gave the company a “neutral” rating in a research report on Tuesday, February 10th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.88.

Insider Activity

In other news, Director Robert L. Denton sold 3,922 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $32.38, for a total value of $126,994.36. Following the transaction, the director owned 3,803 shares in the company, valued at approximately $123,141.14. The trade was a 50.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.66% of the company’s stock.

COPT Defense Properties Trading Down 0.1%

Shares of NYSE CDP opened at $32.60 on Monday. The company has a debt-to-equity ratio of 1.63, a quick ratio of 2.85 and a current ratio of 2.85. COPT Defense Properties has a 52-week low of $26.91 and a 52-week high of $33.33. The firm has a 50 day moving average price of $31.78 and a two-hundred day moving average price of $30.92. The stock has a market cap of $3.70 billion, a P/E ratio of 23.63 and a beta of 0.79.

COPT Defense Properties (NYSE:CDP) last announced its quarterly earnings results on Monday, April 27th. The company reported $0.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.68 by ($0.34). COPT Defense Properties had a net margin of 20.10% and a return on equity of 10.02%. The business had revenue of $200.64 million during the quarter, compared to analyst estimates of $185.10 million. During the same quarter last year, the company posted $0.65 earnings per share. The company’s revenue was up 6.8% compared to the same quarter last year. COPT Defense Properties has set its FY 2026 guidance at 2.730-2.790 EPS and its Q2 2026 guidance at 0.680-0.700 EPS. As a group, equities analysts forecast that COPT Defense Properties will post 2.78 EPS for the current year.

COPT Defense Properties Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Tuesday, June 30th will be given a $0.32 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.9%. COPT Defense Properties’s payout ratio is 92.75%.

About COPT Defense Properties

COPT Defense Properties (NYSE: CDP) is a real estate investment trust organized to own, lease and manage healthcare and life science facilities serving the United States federal government, with a particular focus on Department of Defense and Veterans Affairs tenants. The company was formed in 2016 through a spin-off from Corporate Office Properties Trust, enabling it to concentrate exclusively on medical office buildings and specialized research facilities situated on or near military and federal research campuses.

The company’s portfolio comprises purpose-built, Class A medical office and outpatient specialty clinics, as well as life science laboratories.